Roundview Capital’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $406K | Sell |
6,693
-1,122
| -14% | -$65.4K | 0.03% | 278 |
|
|
2025
Q4 | $422K | Sell |
7,815
-1,450
| -16% | -$69.8K | 0.03% | 271 |
|
|
2025
Q3 | $418K | Hold |
9,265
| – | – | 0.03% | 274 |
|
|
2025
Q2 | $429K | Sell |
9,265
-1,932
| -17% | -$94.8K | 0.03% | 272 |
|
|
2025
Q1 | $683K | Buy |
11,197
+95
| +0.9% | +$5.54K | 0.05% | 232 |
|
|
2024
Q4 | $628K | Sell |
11,102
-219
| -2% | -$12.2K | 0.04% | 250 |
|
|
2024
Q3 | $586K | Sell |
11,321
-2,601
| -19% | -$122K | 0.04% | 257 |
|
|
2024
Q2 | $578K | Sell |
13,922
-1,161
| -8% | -$52K | 0.05% | 244 |
|
|
2024
Q1 | $818K | Sell |
15,083
-4,071
| -21% | -$207K | 0.07% | 223 |
|
|
2023
Q4 | $983K | Sell |
19,154
-9,341
| -33% | -$490K | 0.09% | 199 |
|
|
2023
Q3 | $1.65M | Sell |
28,495
-2,693
| -9% | -$165K | 0.17% | 132 |
|
|
2023
Q2 | $1.99M | Sell |
31,188
-117
| -0.4% | -$7.85K | 0.19% | 120 |
|
|
2023
Q1 | $2.17M | Sell |
31,305
-56
| -0.2% | -$3.95K | 0.23% | 110 |
|
|
2022
Q4 | $2.26M | Buy |
31,361
+3,589
| +13% | +$271K | 0.26% | 103 |
|
|
2022
Q3 | $1.97M | Buy |
27,772
+3,478
| +14% | +$252K | 0.25% | 107 |
|
|
2022
Q2 | $1.87M | Sell |
24,294
-337
| -1% | -$25.7K | 0.22% | 119 |
|
|
2022
Q1 | $1.8M | Buy |
24,631
+1,135
| +5% | +$76.2K | 0.18% | 130 |
|
|
2021
Q4 | $1.47M | Sell |
23,496
-15,613
| -40% | -$916K | 0.15% | 154 |
|
|
2021
Q3 | $2.31M | Buy |
39,109
+3,013
| +8% | +$198K | 0.26% | 102 |
|
|
2021
Q2 | $2.41M | Buy |
36,096
+11
| +0% | +$717 | 0.27% | 96 |
|
|
2021
Q1 | $2.28M | Buy |
36,085
+680
| +2% | +$42.3K | 0.29% | 89 |
|
|
2020
Q4 | $2.2M | Sell |
35,405
-967
| -3% | -$59.5K | 0.3% | 85 |
|
|
2020
Q3 | $2.19M | Sell |
36,372
-2,725
| -7% | -$164K | 0.34% | 72 |
|
|
2020
Q2 | $2.3M | Buy |
39,097
+2,393
| +7% | +$143K | 0.39% | 64 |
|
|
2020
Q1 | $2.05M | Buy |
36,704
+10,451
| +40% | +$639K | 0.43% | 61 |
|
|
2019
Q4 | $1.69M | Buy |
26,253
+4,746
| +22% | +$272K | 0.32% | 92 |
|
|
2019
Q3 | $1.09M | Sell |
21,507
-2,135
| -9% | -$100K | 0.24% | 119 |
|
|
2019
Q2 | $1.07M | Sell |
23,642
-6,130
| -21% | -$286K | 0.24% | 116 |
|
|
2019
Q1 | $1.42M | Sell |
29,772
-816
| -3% | -$40.6K | 0.34% | 86 |
|
|
2018
Q4 | $1.59M | Buy |
30,588
+1,539
| +5% | +$82.7K | 0.45% | 73 |
|
|
2018
Q3 | $1.8M | Buy |
29,049
+111
| +0.4% | +$6.59K | 0.45% | 70 |
|
|
2018
Q2 | $1.6M | Buy |
28,938
+14,855
| +105% | +$802K | 0.42% | 78 |
|
|
2018
Q1 | $891K | Sell |
14,083
-1,410
| -9% | -$90.7K | 0.25% | 112 |
|
|
2017
Q4 | $949K | Buy |
15,493
+3,033
| +24% | +$190K | 0.25% | 111 |
|
|
2017
Q3 | $794K | Sell |
12,460
-920
| -7% | -$53.7K | 0.23% | 118 |
|
|
2017
Q2 | $746K | Buy |
13,380
+800
| +6% | +$43.5K | 0.22% | 124 |
|
|
2017
Q1 | $684K | Buy |
12,580
+160
| +1% | +$8.78K | 0.21% | 128 |
|
|
2016
Q4 | $726K | Buy |
12,420
+100
| +0.8% | +$5.47K | 0.23% | 116 |
|
|
2016
Q3 | $664K | Buy |
12,320
+4,568
| +59% | +$293K | 0.23% | 113 |
|
|
2016
Q2 | $570K | Hold |
7,752
| – | – | 0.21% | 119 |
|
|
2016
Q1 | $495K | Sell |
7,752
-800
| -9% | -$50.5K | 0.18% | 128 |
|
|
2015
Q4 | $588K | Hold |
8,552
| – | – | 0.23% | 109 |
|
|
2015
Q3 | $506K | Sell |
8,552
-155
| -2% | -$9.83K | 0.22% | 110 |
|
|
2015
Q2 | $579K | Hold |
8,707
| – | – | 0.22% | 103 |
|
|
2015
Q1 | $562K | Hold |
8,707
| – | – | 0.22% | 103 |
|
|
2014
Q4 | $514K | Sell |
8,707
-790
| -8% | -$44.6K | 0.21% | 106 |
|
|
2014
Q3 | $486K | Hold |
9,497
| – | – | 0.22% | 91 |
|
|
2014
Q2 | $461K | Buy |
9,497
+246
| +3% | +$12.1K | 0.19% | 113 |
|
|
2014
Q1 | $481K | Hold |
9,251
| – | – | 0.23% | 95 |
|
|
2013
Q4 | $492K | Sell |
9,251
-150
| -2% | -$7.64K | 0.23% | 104 |
|
|
2013
Q3 | $435K | Sell |
9,401
-6
| -0.1% | -$263 | 0.23% | 96 |
|
|
2013
Q2 | $420K | Buy |
+9,407
| New | +$408K | 0.26% | 87 |
|
Other funds holding BMY
VCM
VPM
Roundview Capital's BMY Position: Q1 2026 in Review
Roundview Capital reduced its Bristol-Myers Squibb (BMY) stake by 14% in Q1 2026, selling an estimated $65.4K and leaving 6,693 shares worth $406K. The position accounts for 0.03% of the portfolio, ranked #278.
Roundview Capital first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.41M in Q2 2021. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Roundview Capital held 6,693 shares of Bristol-Myers Squibb worth $406K as of Q1 2026.
- Roundview Capital sold 1,122 Bristol-Myers Squibb shares in Q1 2026, an estimated $65.4K.
- Bristol-Myers Squibb made up 0.03% of Roundview Capital's portfolio in Q1 2026, its #278 holding.
- Roundview Capital first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
- Roundview Capital's Bristol-Myers Squibb position peaked at $2.41M in Q2 2021.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Roundview Capital's 13F filing for Q1 2026, filed 8 May 2026.